Therapeutic Solutions International Reports Synergistic Suppression of Suicide-Associated Neuroinflammatory Pathway by QuadraMune™ and Minocycline

Rhea-AI Summary

Therapeutics Solution International (OTC: TSOI) announced the filing of a patent showing synergy between QuadraMune™ and Minocycline in generating T regulatory cells, which help suppress inflammation. This is significant for conditions like suicidal ideation and COVID-19 mortality risks. QuadraMune™, currently in clinical trials for COVID-19 prevention, could aid in developing treatments for suicides from an immunological viewpoint. The combination may offer long-lasting therapeutic effects against neuroinflammation, with potential applications in other neurodegenerative diseases.

Positive

• Patent filed for the combination of QuadraMune™ and Minocycline highlighting potential for T regulatory cell generation.
• QuadraMune™ is in clinical trials for COVID-19 prevention.
• The combination may offer long-lasting effects on neuroinflammation and could address suicide prevention.

Negative

• None.

OCEANSIDE, Calif., Aug. 28, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported filing a patent on new data showing synergy between QuadraMune™ and Minocycline in generating a type of immune cell termed T regulatory cell. 

T regulatory cells suppress pathological inflammation, including interleukin-6, which is associated with suicidal ideation, as well as risk of COVID-19 associated death.

QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1].  Minocycline is an antibiotic that is approved by the FDA.

"The recent data supports initiation of clinical trials combining QuadraMune and Minocycline for reduction of suicidal ideations and hopefully preventing suicides" said Kalina O'Connor, Director of the Campbell Neurosciences Division of Therapeutic Solutions International and co-inventor of the patent.  "I am thankful to Mr. Dixon and the team at TSOI for having the courage to attack suicide as a biological disease."

Campbell Neurosciences was formed as a Division of the Company to address suicide from an immunological perspective.  The company is named after Kathleen Campbell, the mother of Kalina O'Connor, who was a victim of suicide.

"The potent generation of T regulatory cells by the combination of QuadraMune™ and Minocycline suggests that the therapeutic effects of the combination may be long lasting due to the fact that T regulatory cells have a long life in the body and can replicate" said Famela Ramos, Director of Business Development. "The ability of the T regulatory cells generated to suppress interleukin-6 and macrophage activation supports the possible use of this combination for other neurogenerative diseases associated with inflammation."

"By combining quantitative measurements such as the Campbell Score™, with practical interventions such as QuadraMune™ with adjuvants such as Minocycline,  we believe that we are primed for initiating a new way of treating suicide based on objective immunology and not speculation" said Timothy Dixon, President and CEO of the Company and co-inventor of the patent. "We thank our Scientific Advisory Board for their leadership in stimulating us to explore this fascinating and underdeveloped area of medicine."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

[1] https://clinicaltrials.gov/ct2/show/NCT04421391

Therapeutic Solutions International, Inc.
ir@tsoimail.com

 

View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-reports-synergistic-suppression-of-suicide-associated-neuroinflammatory-pathway-by-quadramune-and-minocycline-301120336.html

SOURCE Therapeutic Solutions International

FAQ

What is the significance of the patent filed by Therapeutics Solutions International on Aug 28, 2020?

The patent demonstrates the synergy between QuadraMune™ and Minocycline in generating T regulatory cells, which could aid in suppressing inflammation related to suicidal ideation and COVID-19 risks.

How does QuadraMune™ relate to COVID-19 according to TSOI's announcement?

QuadraMune™ is currently undergoing clinical trials aimed at preventing COVID-19.

What are T regulatory cells and why are they important in TSOI's research?

T regulatory cells help suppress pathological inflammation, making them crucial in addressing conditions like suicidal ideation and reducing risks associated with COVID-19.

What potential applications does TSOI's research suggest for the combination of QuadraMune™ and Minocycline?

The combination may have therapeutic applications beyond suicide prevention, potentially benefiting other neurodegenerative diseases linked to inflammation.